SEDASYS(®), airway, oxygenation, and ventilation: anticipating and managing the challenges

Dig Dis Sci. 2014 May;59(5):920-7. doi: 10.1007/s10620-013-2996-z. Epub 2014 Jan 8.

Abstract

In May 2013, the FDA (Federal Drug Administration) approved SEDASYS(®), a device that enables non-anesthesia physicians to provide mild-to-moderate sedation to patients undergoing colonoscopy and esophagogastroduodenoscopy. SEDASYS(®) is the first among the devices being built to provide computer-assisted personalized sedation. Although the intention of this approval is to cut the anesthesia related expenses, it is likely to create new challenges to the users-both clinical and administrative-that might even increase the cost. Deep sedation is required frequently for a successful completion of the procedure, which poses unforeseen challenges. The present review aims to provide clear information to the users regarding pre-procedure assessment, possible sedation related complications and management options.

Publication types

  • Review

MeSH terms

  • Conscious Sedation / instrumentation*
  • Conscious Sedation / methods
  • Deep Sedation / instrumentation*
  • Deep Sedation / methods
  • Drug Therapy, Computer-Assisted / adverse effects
  • Drug Therapy, Computer-Assisted / instrumentation*
  • Drug Therapy, Computer-Assisted / methods
  • Humans
  • Hypnotics and Sedatives / administration & dosage*
  • Hypnotics and Sedatives / adverse effects
  • Monitoring, Physiologic / instrumentation*

Substances

  • Hypnotics and Sedatives